Hans Barella has, for the past 30 years, occupied several key positions at Philips Medical Systems, including commercial, marketing and technical roles. He became member of the top management team in 1985 and was appointed President and CEO of Philips Medical Systems in 1997. In this role, he initiated an ambitious acquisition program and consolidated five major companies into one organization dedicated to diagnostics, treatment and patient monitoring.

Additionally, from 1992 to 1996, he was Chairman of COCIR:  the European Coordination Committee of the Radiological, Electromedical and Healthcare IT Industry.

Hans Barella has been a member of the Board of Directors of Elekta AB, Sweden since 2003.

Mr. Barella has a Masters of Business Administration (MBA) and an Electronic Engineering degree.

Between 1993 and 1996, Philippe Boucheron worked at BioCapital LP, one of the largest Canadian venture capital funds, focusing on biotechnology.

From 1997 to 2000, he directed the mid-caps equity research team at ING Barings Ferri, Paris. Here, he spent a significant part of his time following French and European biotech companies.

In 2000, he co-founded Bioam and became the Investment Manager, then a Managing Partner in 2004. He sits on the boards of Aureus Pharma, Libragen, Ademtech, Integragen, Cryolog, SSI and TxCell.

After the merger of Bioam with CDC entreprises in July 2010, Philippe Boucheron joined the direct investment in life sciences  team of CDC entreprises.

Aris started his career at Bankers Trust where he was a structurer of innovative derivative products.  He has more than 14 years of experience with European venture capital and private equity, including Deutsche Bank’s and Credit Suisse First Boston’s funds. 

He holds Mechanical Engineering degrees from Imperial College and MIT an MBA from Insead.

Olivier serves on the boards of Noxxon Pharma (Berlin), Endosense (Geneva), JenaValve (Munich), and Probiodrug (Halle), as well as SuperSonic Imagine.  Up until its acquisition by AstraZeneca, he was also a member of the board of Novexel (France).

Before joining EdRIP, Olivier spent six years with 3i’s life science venture capital practice, based first in Munich and then in Paris. In this position, he served on the boards of several portfolio companies and made a range of international investments. Before joining 3i in 2000, he worked as a strategy consultant with Mercer Management Consulting, both in Munich and Paris.

Olivier holds a PhD in molecular microbiology from the Institut für Mikrobiologie at the University of Munich and performed his scientific research work over several years in Munich and Oxford.

Alexia Perouse has particularly followed the companies Biolipox (merged with Orexo in 2007) and Mutabilis (sold to Pharma Omnium International in 2009).
She has invested in Fovea Pharmaceuticals (sold to Sanofi Aventis in 2009). In addition of her investment in SuperSonic Imagine since the Serie A, she has developed the Medtech portfolio through numerous investments in Cellnovo, CircuLite, Eos Imaging, EyeTechCare, SpineGuard and Stentys (IPO in 2010). She currently sits at 6 boards.
Before joining the venture capital within Sofinnova Partners and then  CAPE in 2005, Alexia Perouse has carried out missions of consulting & business development at Parteurop Développement for biotech start-ups. She started her career as an analyst at Chiron Vaccines.

His track record in life sciences investments includes Seporga, Genset, Biomatech, Coletica and Flamel Technologies. Paul-Louis has also invested in software and electronics segments. He has been a board member of  the Association Française des Investisseurs en Capital (A.F.I.C.), formerly worked for Veolia Group.

Paul-Louis is a graduate of I.E.P. de Paris (Sciences Po.) and holds a Master in Economics .

Jean-Michele began his career in Research & Development for Sumitomo Rubber Industries.  After a move to Canada, he joined Innovatech du Grand Montreal and later CDP Capital where he was actively involved in capital investment projects for companies in Europe, USA and Canada.

He joined ICSO Private Equity in 2003.

Jean-Michele Petit is a graduate in chemistry from the Ecole National Supérieure de Chimie de Paris. He also holds an MBA in Buisness Administration from McGill University, Montreal.

Prior to working in the venture capital industry, Erich spent 15 years with BASF Pharma Knoll AG, including 10 years as an executive board member with worldwide responsibility for preclinical and clinical R&D. He also obtained worldwide patents for five products in cardiovascular, metabolic and pain releif. In 1993, he established a partnership with Cambridge Antibody Technology (CAT), which led to the successful development of Humira.